The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2020 | Highlights in multiple myeloma at ASCO 2020
Thomas Martin, MD, of the Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, explores key presentations on multiple myeloma at ASCO 2020, including results from the ENDURANCE study (NCT01863550), comparing RVD and kRD, as well as updates in the Phase II KarMMa study (NCT03361748), and CARTITUDE-1 (NCT03548207), both BCMA targeting CAR-T cell therapies. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
